Titan Pharmaceuticals (NASDAQ:TTNP – Get Free Report) announced its earnings results on Thursday. The specialty pharmaceutical company reported ($0.85) earnings per share (EPS) for the quarter, Zacks reports.
Titan Pharmaceuticals Trading Down 2.2 %
Shares of NASDAQ TTNP opened at $3.58 on Friday. Titan Pharmaceuticals has a 12 month low of $3.03 and a 12 month high of $14.80. The stock has a 50 day moving average of $3.61 and a 200-day moving average of $4.09.
Wall Street Analyst Weigh In
Separately, StockNews.com assumed coverage on Titan Pharmaceuticals in a research report on Monday. They set a “sell” rating on the stock.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder.
See Also
- Five stocks we like better than Titan Pharmaceuticals
- How to Read Stock Charts for Beginners
- Could Palantir’s R1 Deal Be the Catalyst for a Stock Surge?
- What is the Shanghai Stock Exchange Composite Index?
- Lucid’s Stock Comeback—Is a Long-Term Recovery Ahead?
- What is the Dogs of the Dow Strategy? Overview and Examples
- BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
